At a glance
- Originator Solural Pharma
- Class Antiandrogens; Antineoplastics
- Mechanism of Action CYP17A1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 08 Dec 2015 SOL 804 is available for licensing as of 08 Dec 2015. http://soluralpharma.com/project/
- 08 Dec 2015 Preclinical trials in Prostate cancer in Denmark (PO) prior to December 2015 (Solural pipeline, December 2015)